{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RhuMab-E25",
    "query": {
      "intervention": "RhuMab-E25"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RhuMab-E25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T08:58:30.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02570984",
      "title": "Preventing Asthma in High Risk Kids",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": "47 Months",
        "sex": "ALL",
        "summary": "24 Months to 47 Months"
      },
      "enrollment_count": 200,
      "start_date": "2018-11-27",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • San Diego, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02570984"
    },
    {
      "nct_id": "NCT00472030",
      "title": "Efficacy and Safety of Omalizumab in Bullous Pemphigoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-10-16",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00472030"
    },
    {
      "nct_id": "NCT02654145",
      "title": "Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 100mg SC",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol MDIs",
          "type": "DRUG"
        },
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2016-03-17",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Riverside, California • Roseville, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654145"
    },
    {
      "nct_id": "NCT00367016",
      "title": "Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Allergic Rhinitis",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 6,
      "start_date": "2004-02",
      "completion_date": "2012-10-17",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00367016"
    },
    {
      "nct_id": "NCT00350376",
      "title": "Impact of Asthma Treatments on Daily Activities",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma",
        "Allergies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ovation Research Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1500,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-10",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00350376"
    },
    {
      "nct_id": "NCT00123630",
      "title": "A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophagitis"
      ],
      "interventions": [
        {
          "name": "omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "12 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-11",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123630"
    },
    {
      "nct_id": "NCT01922037",
      "title": "A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 806,
      "start_date": "2013-06-19",
      "completion_date": "2016-03-31",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 145,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01922037"
    },
    {
      "nct_id": "NCT04060550",
      "title": "Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis With a History of Eczema Herpeticum",
        "Atopic Dermatitis Without a History of Eczema Herpeticum",
        "Health Controls Without Atopy"
      ],
      "interventions": [
        {
          "name": "Xolair",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-01-09",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060550"
    },
    {
      "nct_id": "NCT00219323",
      "title": "Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 133,
      "start_date": "2003-11",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2011-10-25",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 0,
      "location_summary": "Not listed",
      "locations": [],
      "official_url": "https://clinicaltrials.gov/study/NCT00219323"
    },
    {
      "nct_id": "NCT05332067",
      "title": "Omalizumab Before Onset of Exacerbations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Atopy",
        "Viral Upper Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 300,
      "start_date": "2022-05-01",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-09-12T08:58:30.014Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332067"
    }
  ]
}